Ocugen, Inc.
OCGN
Rank in Stocks
#14348
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase,... Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Share Price
$0.9721
Last synced: 2026-11-09
Market Cap
$329.65M
Change (1 day)
5.09%
Change (1 year)
-26.91%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Ocugen, Inc. (OCGN)
Category
Healthcare
EPS for Ocugen, Inc. (OCGN)
EPS as of September 2026 TTM: $-0.20
According to Ocugen, Inc.'s latest financial reports, its current EPS (TTM) is $-0.20. At the end of 2025 the company had an EPS of $-0.23, a decrease compared to its 2024 EPS of $-0.20.
EPS history for Ocugen, Inc. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.20 | -13.04% |
| 2025 | $-0.23 | 15.00% |
| 2024 | $-0.20 | -23.08% |
| 2023 | $-0.26 | -35.00% |
| 2022 | $-0.40 | 33.33% |
| 2021 | $-0.30 | -3.23% |
| 2020 | $-0.31 | -79.74% |
| 2019 | $-1.53 | -89.06% |
| 2018 | $-13.98 | -80.00% |
| 2017 | $-69.91 | 2.49% |
| 2016 | $-68.21 | -53.03% |
| 2015 | $-145.22 | -83.71% |
| 2014 | $-891.47 | 637.18% |
| 2013 | $-120.93 | 51.83% |
| 2012 | $-79.65 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -7,930.00% |
US
|
|
| $-7.07 | 3,435.00% |
US
|
|
| $-5.29 | 2,545.00% |
AU
|
|
| $12.88 | -6,540.05% |
BE
|
|
| $21.56 | -10,880.00% |
NL
|
Questions about Ocugen, Inc.'s earnings per share (EPS)
What is Ocugen, Inc.'s earnings per share (EPS)?
Ocugen, Inc.'s earnings per share (EPS) over the last twelve months is $-0.20, as of Sep 2026.
What was Ocugen, Inc.'s earnings per share (EPS) in 2025?
In 2025, Ocugen, Inc.'s earnings per share (EPS) was $-0.23, compared with $-0.20 in 2024.
How has Ocugen, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Ocugen, Inc.'s earnings per share (EPS) was highest in 2024 ($-0.20) and lowest in 2022 ($-0.40).
How does Ocugen, Inc.'s earnings per share (EPS) compare with similar companies?
Ocugen, Inc.'s earnings per share (EPS) ($-0.20) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.